Cited by 44Bipolar Disorder and TreatmentSchizophrenia research and treatmentTreatment of Major Depression

Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms

Open access
Mallinger, Alan G, Thase, Michael E, Haskett, Roger, Buttenfield, Joan, Luckenbaugh, David A, Frank, Ellen, Kupfer, David J, Manji, Husseini K·2008·Bipolar Disorders

Abstract

Objectives: Attenuation of protein kinase C (PKC) is a mechanism common to both established (lithium, valproate) and some novel (tamoxifen) antimanic agents. Verapamil, although primarily known as a calcium channel blocker, also has PKC inhibitory activity. Verapamil has shown antimanic activity in some but not all studies. Therefore, we investigated verapamil, used alone or as an adjunctive treatment, in manic patients who did not respond to an initial adequate trial of lithium. Methods: Each study phase lasted three weeks. Subjects were treated openly with lithium in Phase 1 (n = 45). Those who failed to respond were randomly assigned to double‐blind treatment in Phase 2 with either verapamil (n = 10) or continued‐lithium (n = 8). Phase 2 nonresponders (n = 10) were assigned to combined verapamil/lithium in Phase 3. Results: Response in Phase 2 did not differ significantly between verapamil and continued‐lithium. During Phase 3, response to combined treatment was significantly better than overall response to monotherapy in Phase 2 (Fisher’s Exact test, p = 0.043). Mania ratings improved during combined treatment in Phase 3 by 88.2% (linear mixed model analysis,F = 4.34, p = 0.013), compared with 10.5% improvement during Phase 2. Conclusions: In this preliminary investigation, verapamil monotherapy did not demonstrate antimanic efficacy. By contrast, the combination of verapamil plus lithium was highly efficacious. Our findings thus suggest that verapamil may have potential utility as an adjunct to lithium. This effect may be mediated by additive actions on PKC inhibition, which may be an important mechanism for antimanic agents in general.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1399-5618.2008.00636.x

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mallinger, A. G., Thase, M. E., Haskett, R., Buttenfield, J., Luckenbaugh, D. A., Frank, E., Kupfer, D. J., & Manji, H. K.
Affiliations
  • National Institutes of Health (US)
  • University of Pittsburgh (US)
Corresponding author
Mallinger, Alan G
Venue
Bipolar Disorders
Publisher
Wiley
Published
2008-11-18
Volume
10
Issue
8
Pages
856-866
ISSN
  • 1398-5647 (ISSN-L)
  • 1399-5618
OpenAlex
W2047833434
Cited by
44
References
67
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 2 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 4 · 2013: 6 · 2012: 3
FWCI
1.64
Type
journal article
Language
en
Open access
Locations
  • Bipolar Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5r01mh050634-03)
  • National Institute of Mental Health (MH 29618, MH-50634, R01MH029618, R37MH029618)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
verapamil, lithium, mania, bipolar disorder, protein kinase C inhibition, adjunctive therapy, treatment-resistant mania, combination therapy, calcium channel blockers
MeSH terms
Adult, Bipolar Disorder, Calcium Channel Blockers, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Perphenazine, Psychiatric Status Rating Scales, Antipsychotic Agents, Verapamil, Lithium Carbonate, Antimanic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review